LARIAM SUMMARY
LARIAM®
brand of
mefloquine hydrochloride
TABLETS
Lariam (mefloquine hydrochloride) is an antimalarial agent available as 250-mg tablets of mefloquine hydrochloride (equivalent to 228.0 mg of the free base) for oral administration.
Lariam is indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of
P. falciparum
(both chloroquine-susceptible and resistant strains) or by
Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by
P. ovale
or
P. malariae.
Note:
Patients with acute
P. vivax
malaria, treated with Lariam, are at high risk of relapse because Lariam does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with Lariam, patients should subsequently be treated with an 8-aminoquinoline derivative (eg, primaquine).
Lariam is indicated for the prophylaxis of
P. falciparum
and
P. vivax
malaria infections, including prophylaxis of chloroquine-resistant strains of
P. falciparum.
|
